Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice.
Vincent Lambert,Julie Lecomte,Sylvain Hansen,Silvia Blacher,Maria-Luz Alvarez Gonzalez,Ingrid Struman,Nor Eddine Sounni,Eric Rozet,Pascal De Tullio,Jean-Michel Foidart,Jean-Marie Rakic,Agnès Noël +11 more
TLDR
This standardized protocol can be applied to transgenic mice and can include treatments with drugs, recombinant proteins, antibodies, adenoviruses and pre-microRNAs to aid in the search for new molecular regulators and the identification of novel targets for innovative treatments.Abstract:
The mouse model of laser-induced choroidal neovascularization (CNV) has been used extensively in studies of the exudative form of age-related macular degeneration (AMD). This experimental in vivo model relies on laser injury to perforate Bruch's membrane, resulting in subretinal blood vessel recruitment from the choroid. By recapitulating the main features of the exudative form of human AMD, this assay has served as the backbone for testing antiangiogenic therapies. This standardized protocol can be applied to transgenic mice and can include treatments with drugs, recombinant proteins, antibodies, adenoviruses and pre-microRNAs to aid in the search for new molecular regulators and the identification of novel targets for innovative treatments. This robust assay requires 7-14 d to complete, depending on the treatment applied and whether immunostaining is performed. This protocol includes details of how to induce CNV, including laser induction, lesion excision, processing and different approaches to quantify neoformed vasculature.read more
Citations
More filters
Journal ArticleDOI
A Two-Stage Laser-Induced Mouse Model of Subretinal Fibrosis Secondary to Choroidal Neovascularization
Karis Little,María Llorián-Salvador,Miao Tang,Xuan Du,Órlaith O'Shaughnessy,Gemma McIlwaine,Mei Chen,Heping Xu +7 more
TL;DR: The two-stage laser treatment induced subretinal fibrovascular membranes that persist over 40 days and is a useful tool to study the mechanism of macular fibrosis in nAMD and test antifibrotic drugs.
Journal ArticleDOI
Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration.
Nathan G. Lambert,Xiaohui Zhang,Ruju R. Rai,Hironori Uehara,Susie Choi,Lara S Carroll,Subrata Das,Judd Cahoon,Brian H. Kirk,Blaine M. Bentley,Balamurali K. Ambati,Balamurali K. Ambati +11 more
TL;DR: Findings suggest that AAV2.COMP-Ang1 has potential to serve as an alternative or complementary option to anti-VEGF agents for the long-term amelioration of neovascular AMD.
Journal ArticleDOI
Effect of Anti-C5a Therapy in a Murine Model of Early/Intermediate Dry Age-Related Macular Degeneration.
Christopher B. Toomey,Christopher B. Toomey,Michael Landowski,Mikael Klingeborn,Una Kelly,John R. Deans,Holly Dong,Ons Harrabi,Thomas Van Blarcom,Yik Andy Yeung,Ruslan Grishanin,John C. Lin,Daniel R. Saban,Catherine Bowes Rickman +13 more
TL;DR: Results show that immunotherapy targeting C5a is not sufficient to block the development of the AMD-like pathologies observed in Cfh+/−∼HFC mice and suggest that other complement components or molecules/mechanisms may be driving “early” and “intermediate” AMD pathologies.
Journal ArticleDOI
Intravitreal TSG-6 suppresses laser-induced choroidal neovascularization by inhibiting CCR2 + monocyte recruitment
TL;DR: Results demonstrate that TSG-6 inhibits inflammation and CCR2+ monocyte recruitment into the choroid, and suppresses the development of CNV.
Journal ArticleDOI
Blockage of PI3K/mTOR Pathways Inhibits Laser-Induced Choroidal Neovascularization and Improves Outcomes Relative to VEGF-A Suppression Alone.
TL;DR: Inhibition of PI3K/mTOR pathways may be more effective due to blockade of action of multiple growth factors in mice due to suppression of VEGF-A and other growth factors like platelet-derived growth factor (PDGF).
References
More filters
Journal ArticleDOI
Global data on visual impairment in the year 2002
Serge Resnikoff,Donatella Pascolini,Daniel Etya'ale,Ivo Kocur,Ramachandra Pararajasegaram,Gopal P. Pokharel,Silvio P Mariotti +6 more
TL;DR: Estimates from data on low vision and blindness as defined in the International statistical classification of diseases, injuries and causes of death, 10th revision show cataract remains the leading cause of visual impairment in all regions of the world, except in the most developed countries.
Journal ArticleDOI
Prevalence of age-related macular degeneration in the United States.
David S. Friedman,O'Colmain Bj,Beatriz Munoz,Sandra C. Tomany,Catherine A. McCarty,de Jong Pt,de Jong Pt,de Jong Pt,Barbara Nemesure,Paul Mitchell,Paul Mitchell,John H. Kempen +11 more
TL;DR: In this article, the prevalence and distribution of age-related macular degeneration (AMD) in the United States by age, race/ethnicity, and gender was estimated.
Journal ArticleDOI
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Jeffrey S. Heier,David M. Brown,Victor Chong,Jean-François Korobelnik,Peter K. Kaiser,Quan Dong Nguyen,Bernd Kirchhof,Allen C. Ho,Yuichiro Ogura,George D. Yancopoulos,Neil Stahl,Robert Vitti,Alyson J. Berliner,Yuhwen Soo,Majid Anderesi,Georg Groetzbach,Bernd Sommerauer,Rupert Sandbrink,Rupert Sandbrink,Christian Simader,Ursula Schmidt-Erfurth +20 more
TL;DR: It is demonstrated that aflibercept is an effective treatment for AMD, with the every-2-month regimen offering the potential to reduce the risk from monthly intravitreal injections and the burden of monthly monitoring.
Prevalence of agerelated macular degeneration in the united states
TL;DR: Age-related macular degeneration was far more prevalent among white than among black persons, and the number of persons having AMD will increase by 50% to 2.95 million in 2020.